QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study that will assess the efficacy of AMG 337 in subjects with advanced or
metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion.